305 related articles for article (PubMed ID: 35955671)
1. The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
Iannantuono GM; Torino F; Rosenfeld R; Guerriero S; Carlucci M; Sganga S; Capotondi B; Riondino S; Roselli M
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955671
[TBL] [Abstract][Full Text] [Related]
2. [Current Status and Challenges in Tumor Agnostic Treatment].
Komine K
Gan To Kagaku Ryoho; 2023 Jun; 50(6):657-661. PubMed ID: 37317595
[TBL] [Abstract][Full Text] [Related]
3. Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group.
Vranic S; Basu GD; Hall DW; Gatalica Z
Acta Med Acad; 2022 Dec; 51(3):217-231. PubMed ID: 36799315
[TBL] [Abstract][Full Text] [Related]
4. Application of histology-agnostic treatments in metastatic colorectal cancer.
Sartore-Bianchi A; Agostara AG; Patelli G; Mauri G; Pizzutilo EG; Siena S
Dig Liver Dis; 2022 Oct; 54(10):1291-1303. PubMed ID: 35701319
[TBL] [Abstract][Full Text] [Related]
5. Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications.
Gouda MA; Nelson BE; Buschhorn L; Wahida A; Subbiah V
Clin Cancer Res; 2023 Aug; 29(15):2753-2760. PubMed ID: 37061987
[TBL] [Abstract][Full Text] [Related]
6. Precision medicine becomes reality-tumor type-agnostic therapy.
Yan L; Zhang W
Cancer Commun (Lond); 2018 Mar; 38(1):6. PubMed ID: 29764494
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer.
Tucker MD; Zhu J; Marin D; Gupta RT; Gupta S; Berry WR; Ramalingam S; Zhang T; Harrison M; Wu Y; Healy P; Lisi S; George DJ; Armstrong AJ
Cancer Med; 2019 Aug; 8(10):4644-4655. PubMed ID: 31270961
[TBL] [Abstract][Full Text] [Related]
8. Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report.
Reed-Perino DE; Lai M; Yu EY; Schweizer MT
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37220954
[TBL] [Abstract][Full Text] [Related]
9. Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics.
Tateo V; Marchese PV; Mollica V; Massari F; Kurzrock R; Adashek JJ
Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111371
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.
Abida W; Cheng ML; Armenia J; Middha S; Autio KA; Vargas HA; Rathkopf D; Morris MJ; Danila DC; Slovin SF; Carbone E; Barnett ES; Hullings M; Hechtman JF; Zehir A; Shia J; Jonsson P; Stadler ZK; Srinivasan P; Laudone VP; Reuter V; Wolchok JD; Socci ND; Taylor BS; Berger MF; Kantoff PW; Sawyers CL; Schultz N; Solit DB; Gopalan A; Scher HI
JAMA Oncol; 2019 Apr; 5(4):471-478. PubMed ID: 30589920
[TBL] [Abstract][Full Text] [Related]
11. Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer.
Hwang C; Henderson NC; Chu SC; Holland B; Cackowski FC; Pilling A; Jang A; Rothstein S; Labriola M; Park JJ; Ghose A; Bilen MA; Mustafa S; Kilari D; Pierro MJ; Thapa B; Tripathi A; Garje R; Ravindra A; Koshkin VS; Hernandez E; Schweizer MT; Armstrong AJ; McKay RR; Dorff TB; Alva AS; Barata PC
JAMA Netw Open; 2023 Sep; 6(9):e2334208. PubMed ID: 37721753
[TBL] [Abstract][Full Text] [Related]
12. Use of pembrolizumab among older adults with cancer in the United States, before and after FDA approval of its tumor-agnostic indication.
Hong YD; Enewold L; Halpern MT; Zeruto C; Mariotto AB
Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5745. PubMed ID: 38156547
[TBL] [Abstract][Full Text] [Related]
13. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA.
Barata P; Agarwal N; Nussenzveig R; Gerendash B; Jaeger E; Hatton W; Ledet E; Lewis B; Layton J; Babiker H; Bryce A; Garje R; Stein C; Kiedrowski L; Saylor P; Sartor O
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32788235
[TBL] [Abstract][Full Text] [Related]
14. Impact of tissue-agnostic approvals on management of primary brain tumors.
Ahluwalia MS; Khosla AA; Ozair A; Gouda MA; Subbiah V
Trends Cancer; 2024 Mar; 10(3):256-274. PubMed ID: 38245379
[TBL] [Abstract][Full Text] [Related]
15. Impact of tissue-agnostic approvals for patients with sarcoma.
Pestana RC; Beal JR; Parkes A; Hamerschlak N; Subbiah V
Trends Cancer; 2022 Feb; 8(2):135-144. PubMed ID: 34887213
[TBL] [Abstract][Full Text] [Related]
16. Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine.
Seligson ND; Knepper TC; Ragg S; Walko CM
Clin Pharmacol Ther; 2021 Feb; 109(2):334-342. PubMed ID: 32535906
[TBL] [Abstract][Full Text] [Related]
17. If it's a target, it's a pan-cancer target: Tissue is not the issue.
Adashek JJ; Kato S; Sicklick JK; Lippman SM; Kurzrock R
Cancer Treat Rev; 2024 Apr; 125():102721. PubMed ID: 38522181
[TBL] [Abstract][Full Text] [Related]
18. A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer.
Boiarsky D; Gulhan DC; Savignano H; Lakshminarayanan G; McClure HM; Silver R; Hirsch MS; Sholl LM; Choudhury AD; Ananda G; Park PJ; Tewari AK; Berchuck JE
Clin Genitourin Cancer; 2024 Apr; 22(2):558-568.e3. PubMed ID: 38342659
[TBL] [Abstract][Full Text] [Related]
19. Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond.
Lanka SM; Zorko NA; Antonarakis ES; Barata PC
Curr Oncol; 2023 Apr; 30(4):4246-4256. PubMed ID: 37185436
[TBL] [Abstract][Full Text] [Related]
20. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
